Executive Order on Masks Offers Opportunity to Flatten the COVID-19 Curve

The Infectious Diseases Society of America and its HIV Medicine Association strongly endorse the executive order signed by President Biden today requiring face masks on federal property and other areas of federal authority for the next 100 days to prevent the spread of COVID-19.

Leadership and Funding Can Meet the Challenges of COVID-19: A Vaccine Strategy, Investments in Public Health Are Needed to Stop the Spread of the Virus

The Infectious Diseases Society of America and its HIV Medicine Association strongly support the incoming Administration’s request for $400 billion to strengthen our pandemic response and safely reopen schools.

Accelerated Vaccine Rollout Is Critical to Pandemic Control: Resources and Collaboration Will Be Essential to Success

Plans to significantly accelerate COVID-19 vaccine rollout announced by the Department of Health and Human Services today represent an important step toward controlling the pandemic.

IDSA Foundation Announces More Than $1 Million in Grant Funds Awarded to Researchers Linking Infectious Agents in Alzheimer’s Disease

Ten researchers who are exploring the link between an infectious agent and Alzheimer’s disease have each been awarded $100,000 research grants through the IDSA Foundation’s Microbial Pathogenesis in Alzheimer’s Disease Grant program

HIVMA Appoints Marwan Haddad, MD, MPH, as Chair-Elect

The HIV Medicine Association is pleased to announce the special appointment of Marwan Haddad, MD, MPH, as chair-elect. Dr. Haddad served on the HIVMA Board of Directors from October 2017 to October 2020 and is medical director of the Center for Key Populations for Community Health Center, Inc.

Address COVID-19 Vaccine Access Challenges with Leadership, Funding, Collaboration and Science

The current obstacles to swift and widespread COVID-19 vaccine access are impeding control of the pandemic amid soaring rates of infections, illnesses, hospitalizations and deaths and must be addressed effectively and immediately.

IDSA and HIVMA On Funding Package

The bipartisan bill passed by the House and the Senate and signed by the president provides urgently needed resources to confront COVID-19, funds critical programs across the government in 2021 and offers great hope for recovery from some of the pandemic’s damaging impacts in the year to come.

Response from IDSA President Barbara Alexander MD, MHS, FIDSA, to FDA EUA of Moderna COVID-19 Vaccine: Let’s make the most of this moment

The emergency use authorization of a second COVID-19 vaccine today means that millions more people can be immunized against this virus in the weeks to come.

AABB and IDSA Release Considerations for Clinicians on Emergency Use of COVID-19 Convalescent Plasma

AABB and the Infectious Diseases Society of America issued today a resource document outlining considerations for clinicians on the use of COVID-19 convalescent plasma under the Emergency Use Authorization granted by the Food and Drug Administration.

Response from IDSA President Barbara Alexander MD, MHS, FIDSA to FDA EUA of Pfizer-BioNTech COVID-19 Vaccine: FDA Authorization Is First of Critical Steps Ahead

“The first Emergency Use Authorization of a vaccine against the novel coronavirus in the United States offers a promising opportunity to reverse the trajectory of the COVID-19 pandemic." Read Full Statement

Representatives Introduce PASTEUR Act to Build, Protect Antibiotic Access

Congressional Rep. Mike Doyle (D-PA) and Rep. Drew Ferguson (R-GA) today introduced The Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act

IDSA Submits Comments on NIH COVID-19 Research Plan

In a Dec. 7 letter to National Institutes of Health Director Francis Collins, MD, PhD, on the agency’s Strategic Plan for COVID-19 Research, IDSA President Barbara Alexander, MD, MHS, FIDSA, calls for cross-cutting strategies